Header Logo

Connection

JENNIFER FOSTER to Child

Back to Details
This is a "connection" page, showing publications JENNIFER FOSTER has written about Child.
JENNIFER FOSTER
Connection Strength
0.991
Child
  1. The impact of congenital heart disease on treatment and survival of patients with hepatoblastoma: A single-center experience. Pediatr Blood Cancer. 2024 Nov; 71(11):e31214.
    View in: PubMed
    Score: 0.056
  2. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
    View in: PubMed
    Score: 0.056
  3. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer. 2024 Jan; 71(1):e30732.
    View in: PubMed
    Score: 0.053
  4. Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. J Oncol Pharm Pract. 2022 Jun; 28(4):904-909.
    View in: PubMed
    Score: 0.048
  5. Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. Pediatr Blood Cancer. 2021 07; 68(7):e29056.
    View in: PubMed
    Score: 0.045
  6. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
    View in: PubMed
    Score: 0.044
  7. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. Pediatr Blood Cancer. 2021 03; 68(3):e28871.
    View in: PubMed
    Score: 0.044
  8. Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant. J Pediatr Hematol Oncol. 2020 10; 42(7):e569-e574.
    View in: PubMed
    Score: 0.043
  9. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
    View in: PubMed
    Score: 0.043
  10. Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage. Pediatr Blood Cancer. 2020 09; 67(9):e28334.
    View in: PubMed
    Score: 0.042
  11. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 04; 67(4):e28123.
    View in: PubMed
    Score: 0.041
  12. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Opin Drug Saf. 2018 Dec; 17(12):1257-1262.
    View in: PubMed
    Score: 0.038
  13. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360.
    View in: PubMed
    Score: 0.038
  14. Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant. Pediatr Blood Cancer. 2018 12; 65(12):e27348.
    View in: PubMed
    Score: 0.037
  15. Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant. Pediatr Transplant. 2018 05; 22(3):e13141.
    View in: PubMed
    Score: 0.036
  16. Dinutuximab for the treatment of pediatric patients with neuroblastoma. Drugs Today (Barc). 2017 Sep; 53(9):469-476.
    View in: PubMed
    Score: 0.035
  17. Off-label use of drugs in children. Pediatrics. 2014 Mar; 133(3):563-7.
    View in: PubMed
    Score: 0.027
  18. Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer. 2011 Jul 15; 57(1):163-5.
    View in: PubMed
    Score: 0.022
  19. Drugs Used to Treat Pediatric Emergencies. Pediatrics. 2020 01; 145(1).
    View in: PubMed
    Score: 0.021
  20. Indications and Outcomes for Tracheostomies in Pediatric Oncology Patients-A Single Center Study. Pediatr Blood Cancer. 2025 Feb; 72(2):e31451.
    View in: PubMed
    Score: 0.014
  21. Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001-2020. Cancer Epidemiol. 2024 Oct; 92:102610.
    View in: PubMed
    Score: 0.014
  22. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 01 20; 41(3):508-516.
    View in: PubMed
    Score: 0.012
  23. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.
    View in: PubMed
    Score: 0.012
  24. Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy. Pediatr Blood Cancer. 2023 01; 70(1):e29981.
    View in: PubMed
    Score: 0.012
  25. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022 10; 69(10):e29763.
    View in: PubMed
    Score: 0.012
  26. Associations of demographic and perinatal factors with childhood neuroblastoma in Texas, 1995-2011. Cancer Epidemiol. 2022 06; 78:102165.
    View in: PubMed
    Score: 0.012
  27. Preventing Home Medication Administration Errors. Pediatrics. 2021 12 01; 148(6).
    View in: PubMed
    Score: 0.012
  28. Thoracoscopic Resection of Thoracic Inlet Neuroblastic Tumors in Young Children. J Laparoendosc Adv Surg Tech A. 2021 Dec; 31(12):1475-1479.
    View in: PubMed
    Score: 0.012
  29. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021 Oct 01; 7(10):1550-1558.
    View in: PubMed
    Score: 0.012
  30. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
    View in: PubMed
    Score: 0.011
  31. Characteristics of benign neuroblastic tumors: Is surgery always necessary? J Pediatr Surg. 2022 Aug; 57(8):1538-1543.
    View in: PubMed
    Score: 0.011
  32. Role of anticoagulation in the management of tumor thrombus: A 10-year single-center experience. Pediatr Blood Cancer. 2021 09; 68(9):e29173.
    View in: PubMed
    Score: 0.011
  33. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021 03; 41(2):961-1021.
    View in: PubMed
    Score: 0.011
  34. Severe COVID-19 infection in a child receiving immunotherapy for cancer. Pediatr Blood Cancer. 2021 03; 68(3):e28710.
    View in: PubMed
    Score: 0.011
  35. Blood product administration during high risk neuroblastoma therapy. Pediatr Hematol Oncol. 2020 Feb; 37(1):5-14.
    View in: PubMed
    Score: 0.010
  36. A case series of pediatric oncology patients undergoing successful rapid etoposide desensitization. Pediatr Allergy Immunol. 2019 08; 30(5):579-582.
    View in: PubMed
    Score: 0.010
  37. Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma. Pediatr Blood Cancer. 2019 08; 66(8):e27786.
    View in: PubMed
    Score: 0.010
  38. Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg. 2018 Nov; 53(11):2235-2239.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.